Navigation Links
Texcel Highlights Medical Device Development & Manufacturing Solutions at MD&M West, booth 314
Date:2/4/2009

EAST LONGMEADOW, Mass., Feb. 4 /PRNewswire/ -- Texcel's custom medical device development and manufacturing solutions helps companies around the world accelerate the commercialization of their surgical, interventional, and implantable medical device technologies. Texcel will highlight its full array of services and technologies at the MD&M West Expo, February 10-12, 2009, in exposition booth # 314.

Texcel provides the manufacturing infrastructure and expertise for a wide range of product applications -- from endoscopic surgical instrumentation and spinal/orthopedic implants to total artificial hearts and neurostimulators.

Texcel's specialized services and full medical device solutions include device design, development history file management, quality and regulatory assistance, process validation, along with general manufacturing, electronic testing, laser welding, and clean-room processing for a wide range of product applications.

Texcel, with more than 20 years of experience assisting companies execute increasingly sophisticated designs through reliable manufacturing, has particular expertise in five key areas:

  • Orthopedics, including products ranging from metal bone fastening devices to novel new materials;
  • Cardiac Assist, with expertise helping industry pioneers assemble and produce many types of cardiac assist devices;
  • Active Implantables, including a wide range of metal and non-metal biocompatible materials as well
    '/>"/>

SOURCE Texcel
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
2. Highlights of Economic and Business Growth in the Tampa Bay Region
3. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Highlights of Economic and Business Growth in the Tampa Bay Region
6. Highlights of Economic and Business Growth in the Tampa Bay Region
7. Oncothyreon highlights corporate and clinical objectives for 2008
8. CyberKnife Users Meeting Highlights Major Clinical Data Milestones and Emerging Trends
9. National Nanotechnology Initiative releases its fiscal year 2009 budget and highlights
10. MEDEA+ Noblanc award highlights improvements in microelectronics
11. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... -- , Not for release, publication or distribution ... jurisdiction where to do so would constitute a violation of ... ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG ... has held a meeting with representatives of AbbVie. ... agreement or approval of AbbVie. A further update ...
(Date:7/11/2014)... 11, 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) ... (eslicarbazepine acetate) for use as a once-daily adjunctive therapy ... epilepsy who are not satisfactorily controlled with conventional therapy. ... patients under 18 years of age. ... and according to Epilepsy Canada, it affects 0.6% of ...
(Date:7/10/2014)... Product and process impurities in ... and are often “lost in the noise,” making ... presenters Dr. Rowel Tobias, Senior Scientist, Protein Chemistry ... of Quality at Nanotherapeutics, Inc., to lear about ... detection and quantitation while achieving the required specificity ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... Inc. (Nasdaq: EVVV ),a global endovascular device ... its Board of Directors effective immediately. , ... president and chief executive officer of CCS,Medical, a privately ... diseases such as diabetes, wound care, urology and respiratory,disorders. ...
... and PHILADELPHIA, Dec. 3 GlaxoSmithKline,(LSE/NYSE: GSK ) ... a,pending lawsuit in the previously announced tender offer to purchase ... Inc.,(Nasdaq: GNLB ), for $1.30 per share in ... It is a condition to ...
... Dec. 3 CeloNova BioSciences, Inc., announced,today that ... is commercializing the,CATANIA(TM) Coronary Stent System with NanoThin ... any stent thrombosis in clinical studies. It is ... now some Middle,Eastern countries with aggressive world-wide expansion ...
Cached Biology Technology:ev3 Inc. Appoints John L. Miclot to Board of Directors 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 2GlaxoSmithKline Announces Waiver of a Condition to the Tender Offer for Genelabs Technologies, Inc. 3CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3
(Date:7/11/2014)... July 3, 2014, Shenzhen, China Researchers from Salk ... for the first time evaluated the safety and ... and successfully developed a new method, TALEN-HDAdV, which ... pluripotent stem cell (hiPSC). This study published online ... important theoretical foundation for stem cell-based gene therapy. ...
(Date:7/11/2014)... Researchers have pioneered a revolutionary new way to ... Virtual Finger, allows scientists to move through digital ... using the flat surface of their computer screens. ... orders of magnitude more efficient, saving time, money ... areas of experimental biology. The software and its ...
(Date:7/11/2014)... that under the normal circumstances, astrocytes participate ... neuronal environment, and exhibit therapeutic and repairing ... Previous studies have found that nerve cells ... induction have reduced viability, which produces influences ... Yuan, Kailuan General Hospital, Hebei United University, ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Virtual finger enables scientists to navigate and analyze complex 3D images 2
... learning to swim? Thrashing around, floundering, until suddenly it ... of doggy-paddle propel you away from your parent's arms. ... swimmers. Actually, fish larvae are pretty feeble when it ... Dr Ulrike Müller from Wageningen University studies how fish ...
... breast cancer is the lack of inexpensive, early detection ... Michigan hope to change that by developing a device ... with breast cancer. The team won a Breast Cancer ... reward research proposals that could lead to critical advancements ...
... show that regular use of popular prescription pain relievers may ... percent and may offer similar benefit in the prevention of ... were released today at the annual meeting of the American ... believe this is the first study to show that selective ...
Cached Biology News:Even fish don't swim well when they're young! 2Researchers win money to develop breath test to detect breast cancer 2COX-2 inhibitors significantly reduce risk of cancer 2
prototype Nco I...
... is aseptically collected via cardiac puncture from 3 ... mixed sex). It is then centrifuged and frozen ... filtered and bottled at 4C then stored at ... HAVE ALWAYS USED PEL-FREEZ COMPLEMENT, YOU CAN NOW ...
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Performance, mycoplasma, virus, and endotoxin tested...
Biology Products: